Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bioreactor results shared at CHI Summit
October 2016
SHARING OPTIONS:

MINNEAPOLIS—Cell Culture Company (C3) presented data regarding the steady-state production of monoclonal antibody using automated single-use, scalable perfusion bioreactors at CHI’s 8th Annual Bioprocessing Summit. Scott Waniger, C3’s vice president of BioServices, made the presentation—titled “Use of a Scalable, Continuous Processing Platform to Solve Production Challenges in Mammalian Cell Cultures”—which detailed the long-term benefits of homeostatic pH conditions, metabolite levels (glucose and lactate) and monoclonal antibody production in a hollow fiber perfusion bioreactor. Steady-state conditions were consistent with continuous protein expression for more than 100 days.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.